tiprankstipranks
Advertisement
Advertisement
Hutchmed says NDA for sovleplenib accepted in China
PremiumThe FlyHutchmed says NDA for sovleplenib accepted in China
2M ago
Hutchmed Expands Oncology Pipeline With New First‑in‑Human Solid Tumor Trial
Premium
Company Announcements
Hutchmed Expands Oncology Pipeline With New First‑in‑Human Solid Tumor Trial
3M ago
Hutchmed price target lowered to $20 from $21 at BofA
Premium
The Fly
Hutchmed price target lowered to $20 from $21 at BofA
3M ago
Hutchmed price target lowered to $22 from $25 at BofA
PremiumThe FlyHutchmed price target lowered to $22 from $25 at BofA
5M ago
Hutchmed initiates Phase III stage of Phase II/III trial
Premium
The Fly
Hutchmed initiates Phase III stage of Phase II/III trial
5M ago
Hutchmed initiates Phase III stage of Phase II/III trial
Premium
The Fly
Hutchmed initiates Phase III stage of Phase II/III trial
5M ago
Hutchmed highlights pipeline, business progress at R&D Updates event
PremiumThe FlyHutchmed highlights pipeline, business progress at R&D Updates event
7M ago
Hutchmed’s HMPL-506 Study: A Potential Game-Changer in Hematological Malignancies
Premium
Company Announcements
Hutchmed’s HMPL-506 Study: A Potential Game-Changer in Hematological Malignancies
8M ago
Hutchmed’s Promising Study in Metastatic Pancreatic Cancer: A Potential Game Changer
Premium
Company Announcements
Hutchmed’s Promising Study in Metastatic Pancreatic Cancer: A Potential Game Changer
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100